Literature DB >> 17545722

Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients.

Guglielmo Rosignoli1, Alison Cranage, Catherine Burton, Mark Nelson, Alan Steel, Brian Gazzard, Frances Gotch, Nesrina Imami.   

Abstract

Anergy and defective immune responses are characteristic of chronic HIV-1 infection. The programmed death 1 (PD-1)/PD-1 ligand (PD-L1) pathway appears to be involved in downregulating T-cell functionality. We found raised levels of PD-L1 in aviraemic chronically infected HIV-1-positive patients, which may contribute to incomplete immune reconstitution after treatment with HAART.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17545722     DOI： 10.1097/QAD.0b013e3281de7296

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  16 in total

1.  CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.

Authors:  Samantha J Westrop; Graeme Moyle; Akil Jackson; Mark Nelson; Sundhiya Mandalia; Nesrina Imami
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

2.  Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques.

Authors:  Thorsten Demberg; Egidio Brocca-Cofano; Peng Xiao; David Venzon; Diego Vargas-Inchaustegui; Eun Mi Lee; Irene Kalisz; V S Kalyanaraman; Janet Dipasquale; Katherine McKinnon; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

Review 3.  PD-1 coinhibitory signals: the link between pathogenesis and protection.

Authors:  Deanna A Kulpa; Mariam Lawani; Anthony Cooper; Yoav Peretz; Jeff Ahlers; Rafick-Pierre Sékaly
Journal:  Semin Immunol       Date:  2013-03-31       Impact factor: 11.130

Review 4.  HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape.

Authors:  Virginia Carroll; Alfredo Garzino-Demo
Journal:  Pathog Dis       Date:  2015-06-29       Impact factor: 3.166

5.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Authors:  Cynthia L Gay; Ronald J Bosch; Justin Ritz; Jason M Hataye; Evgenia Aga; Randall L Tressler; Stephen W Mason; Carey K Hwang; Dennis M Grasela; Neelanjana Ray; Josh C Cyktor; John M Coffin; Edward P Acosta; Richard A Koup; John W Mellors; Joseph J Eron
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

Review 6.  Human Immunodeficiency Virus Infection and Host Defense in the Lungs.

Authors:  Tysheena P Charles; Judd E Shellito
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

7.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

8.  Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Authors:  Florin Tuluc; Sergei Spitsin; Nancy B Tustin; Jennifer B Murray; Richard Tustin; Laura A Schankel; Andrew Wiznia; Sharon Nachman; Steven D Douglas
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-18       Impact factor: 2.205

9.  Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.

Authors:  G Rosignoli; C H Lim; M Bower; F Gotch; N Imami
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

10.  PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes.

Authors:  Adriano Boasso; Andrew W Hardy; Alan L Landay; Jeffrey L Martinson; Stephanie A Anderson; Matthew J Dolan; Mario Clerici; Gene M Shearer
Journal:  Clin Immunol       Date:  2008-07-22       Impact factor: 3.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.